Business
Brainomix and Boehringer Ingelheim expand e-Lung AI collaboration for pulmonary fibrosis diagnosis
Data on earlier pulmonary fibrosis diagnosis has pushed Brainomix and Boehringer Ingelheim to expand their collaboration, moving from retrospective...
Bristol Myers Squibb signs USD 15.2b deal with Hengrui for 13 early-stage oncology, hematology programs
Bristol Myers Squibb (NYSE: BMY) is committing up to USD 950 million in near-term structured payments to access a portfolio of 13 early-stage programs from...
Boehringer Ingelheim licenses preclinical anti-inflammatory antibody program from Immunitas for EUR 407.5m
Boehringer Ingelheim has licensed a preclinical antibody program from Immunitas Therapeutics, a Waltham, Massachusetts-based precision immunotherapy...
CEL-SCI raises USD 7.2m in public offering to fund Multikine cancer immunotherapy development
A pattern of recurring equity raises at Vienna-based CEL-SCI Corporation reflects the cash demands of a pre-revenue clinical-stage company advancing a...
Cellular Intelligence acquires Novo Nordisk's clinical-stage Parkinson's cell therapy program globally
Cellular Intelligence, a Boston-based AI-native biotech operating under the legal entity Somite Therapeutics, has acquired global rights to Novo Nordisk's...
AGC Biologics joins Orphan Therapeutics Accelerator's clinical development network as manufacturing partner
AGC Biologics has joined the Orphan Therapeutics Accelerator's (OTXL) clinical development network as a dedicated manufacturing partner, adding ex vivo...
GSK partners with Chia Tai Tianqing Pharmaceutical for bepirovirsen launch in mainland China
GSK is positioning its first-in-class antisense oligonucleotide bepirovirsen for launch in mainland China through an exclusive commercial collaboration with...
Artiva Bio raises USD 300m via share offering to support NK cell therapy pipeline
FDA agreement on a Phase 3 registrational trial design positions Artiva Biotherapeutics for a potential BLA submission in refractory rheumatoid arthritis by...
Odyssey Therapeutics raises USD 304m via Nasdaq IPO, backed by TPG Life Sciences affiliate
An upsized raise of approximately USD 304 million positions Odyssey Therapeutics among the larger clinical-stage biotech listings of the current market...
Gilead's Q1'26 Earnings Call: Anito-cel poised for December PDUFA decision, three acquisitions near inflection points
Gilead Sciences' Q1 2026 earnings conference call, held on May 7, 2026, revealed a company simultaneously managing three major acquisition integrations...
Anagram Therapeutics secures USD 250m strategic investment from Blackstone Life Sciences
Natick, Massachusetts-based Anagram Therapeutics has closed a USD 250 million strategic investment from Blackstone Life Sciences to advance ANG003, a...
ParcelBio raises USD 13m seed financing for next-gen mRNA platform, in vivo CAR-T for auto-immune diseases
San Francisco-based ParcelBio has raised USD 13 million in seed financing to advance its APEXm (Amplified and Prolonged EXpression mRNA) platform and a lead...
GSK licenses Halozyme Enhanze platform for subcutaneous ADCs
GSK (NYSE: GSK) has licensed Halozyme Therapeutics' (Nasdaq: HALO) Enhanze drug delivery platform for subcutaneous formulations of multiple oncology...
Angelini Pharma acquires Catalyst Pharmaceuticals for USD 4.1b to enter US market, expand rare disease portfolio
Italy-based Angelini Pharma S.p.A. has entered into a definitive agreement to acquire Catalyst Pharmaceuticals (Nasdaq: CPRX) for USD 31.50 per share in...
Travere Therapeutics raises USD 475m in convertible debt offering
San Diego-based Travere Therapeutics (Nasdaq: TVTX) announced an upsized convertible debt financing on May 6, 2026, structured primarily to retire a portion...
The AllSci Brief
Systematic R&D and deal news. Daily.